How Was Tremfya Studied? Tremfya was studied in three trials in people who had moderately to severely active Crohn’s disease for at least three months and did not have a good response to other ...

Johnson & Johnson said Monday that its Tremfya drug induced clinical and endoscopic improvements in adult patients with moderately to severely active Crohn's disease (CD).The Phase 2 interim data ...

Crohn's disease affects roughly 780,000 people in the United States and often requires a lifetime of management. Despite numerous available biologic medications, many patients fail to achieve ...

Send comments and news tips to [email protected]. Cite this: Risankizumab in Crohn's Disease: Clinical, Endoscopic Outcomes Remain Stable for up to 3 Years - Medscape - February 23, 2024.

The primary efficacy end points were clinical remission (CDAI < 150) and endoscopic response (Simple Endoscopic Score for Crohn’s Disease [SES-CD] reduction ≥ 50%) at week 12, with additional ...

John R. Saltzman, MD, discusses the most topical issues in endoscopy at DDW 2003, the focus of which is video capsule endoscopy -- a novel technology designed primarily to image the small intestine.

AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.

Fecal microbiota transplantation was not effective at inducing clinical or endoscopic remission in patients with Crohn’s disease, according to study results published in The American Journal of ...

Tremfya is the first approved IL-23 inhibitor to offer both IV and fully subcutaneous induction regimens. This approval for Crohn’s disease may make Tremfya a direct competitor with Stelara.

Crohn’s disease In the CD cohort of the RELIEVE UCCD study, 26% (450 mg) and 48% (900 mg) of patients with CD treated with duvakitug achieved the primary endpoint of endoscopic response (SES-CD)* ...